JP2019536440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536440A5 JP2019536440A5 JP2019518302A JP2019518302A JP2019536440A5 JP 2019536440 A5 JP2019536440 A5 JP 2019536440A5 JP 2019518302 A JP2019518302 A JP 2019518302A JP 2019518302 A JP2019518302 A JP 2019518302A JP 2019536440 A5 JP2019536440 A5 JP 2019536440A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- item
- polypeptide
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims description 309
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 261
- 229920001184 polypeptide Polymers 0.000 claims description 260
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 260
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 69
- 108020001507 fusion proteins Proteins 0.000 claims description 56
- 102000037865 fusion proteins Human genes 0.000 claims description 56
- 238000006467 substitution reaction Methods 0.000 claims description 45
- 108010059616 Activins Proteins 0.000 claims description 21
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 21
- 239000000488 activin Substances 0.000 claims description 21
- 102200151008 rs863225226 Human genes 0.000 claims description 16
- 230000004048 modification Effects 0.000 claims description 15
- 238000012986 modification Methods 0.000 claims description 15
- 239000003446 ligand Substances 0.000 claims description 10
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 10
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 9
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 claims description 3
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 3
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 3
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims description 3
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 claims description 3
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 claims description 3
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 claims description 3
- 102100035363 Growth/differentiation factor 7 Human genes 0.000 claims description 3
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 3
- 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 claims description 3
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 claims description 3
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims description 3
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims description 3
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 claims description 3
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 claims description 3
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 claims description 3
- 101001023968 Homo sapiens Growth/differentiation factor 7 Proteins 0.000 claims description 3
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 claims description 3
- 108010023082 activin A Proteins 0.000 claims description 3
- 108010023079 activin B Proteins 0.000 claims description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000013595 glycosylation Effects 0.000 claims description 3
- 238000006206 glycosylation reaction Methods 0.000 claims description 3
- 125000003473 lipid group Chemical group 0.000 claims description 3
- 230000019491 signal transduction Effects 0.000 claims description 3
- 238000000423 cell based assay Methods 0.000 claims description 2
- 239000000710 homodimer Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 102220558380 Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16_F82K_mutation Human genes 0.000 claims 2
- 102220523693 Ubiquitin-related modifier 1_K55D_mutation Human genes 0.000 claims 2
- 102220346405 c.164A>G Human genes 0.000 claims 2
- 102220157866 rs147372618 Human genes 0.000 claims 2
- 102220517289 Phosphate-regulating neutral endopeptidase PHEX_N83A_mutation Human genes 0.000 claims 1
- 102220261609 rs1554201009 Human genes 0.000 claims 1
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 description 175
- 235000001014 amino acid Nutrition 0.000 description 138
- 239000012634 fragment Substances 0.000 description 56
- 229940024606 amino acid Drugs 0.000 description 44
- 102220480249 G-protein coupled receptor family C group 6 member A_K74A_mutation Human genes 0.000 description 30
- 102220525561 Coiled-coil domain-containing protein 200_A24N_mutation Human genes 0.000 description 15
- 102220567352 Ornithine decarboxylase antizyme 1_K74F_mutation Human genes 0.000 description 15
- 102220633854 PRKCA-binding protein_D80A_mutation Human genes 0.000 description 15
- 102220469872 Protein argonaute-3_E37A_mutation Human genes 0.000 description 15
- 102220495689 Putative uncharacterized protein FLJ43944_R40A_mutation Human genes 0.000 description 15
- 102220469729 Voltage-dependent L-type calcium channel subunit beta-2_D54K_mutation Human genes 0.000 description 15
- 102220479829 Voltage-dependent L-type calcium channel subunit beta-2_R56K_mutation Human genes 0.000 description 15
- 102220100897 rs201542692 Human genes 0.000 description 15
- 102200158858 rs34435255 Human genes 0.000 description 15
- 102220125519 rs562411087 Human genes 0.000 description 15
- 102200089383 rs57977969 Human genes 0.000 description 15
- 102220088131 rs869025353 Human genes 0.000 description 15
- 102220005147 rs34173382 Human genes 0.000 description 14
- 102220577876 Poly(rC)-binding protein 1_W78A_mutation Human genes 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 125000005842 heteroatom Chemical group 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 102200145357 rs1555341957 Human genes 0.000 description 13
- 102220479051 CD59 glycoprotein_L79D_mutation Human genes 0.000 description 11
- 102220575187 Egl nine homolog 1_F82A_mutation Human genes 0.000 description 11
- 102220496976 Platelet-activating factor acetylhydrolase 2, cytoplasmic_L79A_mutation Human genes 0.000 description 11
- 102220542870 Presenilins-associated rhomboid-like protein, mitochondrial_L79E_mutation Human genes 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 8
- 235000018417 cysteine Nutrition 0.000 description 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 239000000833 heterodimer Substances 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- 235000004279 alanine Nutrition 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 235000003704 aspartic acid Nutrition 0.000 description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 6
- 235000013922 glutamic acid Nutrition 0.000 description 6
- 239000004220 glutamic acid Substances 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 4
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 description 4
- 101000799193 Homo sapiens Activin receptor type-1C Proteins 0.000 description 4
- 101000934638 Homo sapiens Bone morphogenetic protein receptor type-1A Proteins 0.000 description 4
- 101000984546 Homo sapiens Bone morphogenetic protein receptor type-1B Proteins 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 102220556625 Acyl-coenzyme A thioesterase 11_K55A_mutation Human genes 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- -1 ALK5 Proteins 0.000 description 1
- 102100034111 Activin receptor type-1 Human genes 0.000 description 1
- 102100034134 Activin receptor type-1B Human genes 0.000 description 1
- 102100034135 Activin receptor type-1C Human genes 0.000 description 1
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 description 1
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023006458A JP7617962B2 (ja) | 2016-10-05 | 2023-01-19 | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404718P | 2016-10-05 | 2016-10-05 | |
| US62/404,718 | 2016-10-05 | ||
| PCT/US2017/055421 WO2018067874A1 (en) | 2016-10-05 | 2017-10-05 | Variant actriib proteins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023006458A Division JP7617962B2 (ja) | 2016-10-05 | 2023-01-19 | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019536440A JP2019536440A (ja) | 2019-12-19 |
| JP2019536440A5 true JP2019536440A5 (enExample) | 2020-11-12 |
| JP7280182B2 JP7280182B2 (ja) | 2023-05-23 |
Family
ID=61831930
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518302A Active JP7280182B2 (ja) | 2016-10-05 | 2017-10-05 | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 |
| JP2023006458A Active JP7617962B2 (ja) | 2016-10-05 | 2023-01-19 | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023006458A Active JP7617962B2 (ja) | 2016-10-05 | 2023-01-19 | バリアントＡｃｔＲＩＩＢタンパク質およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11267865B2 (enExample) |
| EP (1) | EP3523328A4 (enExample) |
| JP (2) | JP7280182B2 (enExample) |
| KR (2) | KR102595559B1 (enExample) |
| CN (1) | CN110036025B (enExample) |
| AU (3) | AU2017338916B2 (enExample) |
| BR (1) | BR112019006918A2 (enExample) |
| CA (1) | CA3039525A1 (enExample) |
| MA (1) | MA46471A (enExample) |
| WO (1) | WO2018067874A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| SMT202300166T1 (it) | 2014-12-03 | 2023-07-20 | Celgene Corp | Antagonisti di attivina- actrii e usi per il trattamento di sindrome mielodisplastica |
| RS61881B1 (sr) | 2015-04-22 | 2021-06-30 | Biogen Ma Inc | Novi hibridni actriib proteini zamke za ligand za lečenje bolesti gubljenja mišića |
| EP3439741A4 (en) | 2016-04-06 | 2020-05-06 | Acceleron Pharma Inc. | ALK7 ANTAGONISTS AND USES THEREOF |
| WO2018067874A1 (en) | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Variant actriib proteins and uses thereof |
| JOP20190085A1 (ar) * | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| EP3538123A4 (en) | 2016-11-10 | 2020-10-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE IIA VARIANTS AND THEIR METHODS OF USE |
| CA3082146A1 (en) | 2017-11-09 | 2019-05-16 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| CN120399032A (zh) | 2018-01-12 | 2025-08-01 | 科乐斯疗法公司 | 激活素受体iib型变体及其使用方法 |
| JP2021522793A (ja) | 2018-05-03 | 2021-09-02 | アクセルロン ファーマ インコーポレイテッド | ＴＧＦβスーパーファミリーリガンドの多特異性バインダーおよびその使用 |
| EP3788067A4 (en) * | 2018-05-03 | 2022-01-19 | Acceleron Pharma Inc. | NOVEL BINDERS OF TGFBETA SUPERFAMILY LIGANDS AND THEIR USES |
| EP3790572A4 (en) | 2018-05-09 | 2022-03-16 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF |
| EP3807308A4 (en) * | 2018-06-15 | 2022-03-16 | Acceleron Pharma Inc. | BI AND TRIFUNCTIONAL FUSION PROTEINS AND THEIR USES |
| CN109293763B (zh) * | 2018-10-26 | 2021-10-26 | 中国农业科学院特产研究所 | 水貂激活素b蛋白及其制备与应用 |
| KR20220088699A (ko) | 2019-09-27 | 2022-06-28 | 디스크 메디슨, 인크. | 골수섬유증 및 관련 상태의 치료 방법 |
| BR112022015387A2 (pt) * | 2020-02-03 | 2022-10-11 | Acceleron Pharma Inc | Proteínas actriib variantes e usos das mesmas |
| EP4121088A4 (en) * | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| WO2021189006A1 (en) * | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iia variants |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| EP4171603A4 (en) * | 2020-06-25 | 2024-06-26 | Gliknik Inc. | ACE2-FC FUSION PROTEINS AND METHODS OF USE |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| EP4274600A4 (en) * | 2021-01-08 | 2024-11-20 | Acceleron Pharma Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY HYPERTENSION |
| IL314280A (en) | 2022-01-28 | 2024-09-01 | 35Pharma Inc | Type IIB activin receptor variants and their uses |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3382562D1 (de) | 1982-09-24 | 1992-06-25 | Us Health | Wiederherstellung von gewebe bei tieren. |
| NZ210699A (en) | 1984-01-04 | 1989-06-28 | Int Genetic Eng | Isolation of an osteogenic protein of the p3 immunologically related family |
| EP0169016B2 (en) | 1984-07-16 | 2004-04-28 | Celtrix Pharmaceuticals, Inc. | Polypeptide cartilage-inducing factors found in bone |
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US20050186593A1 (en) * | 1991-05-10 | 2005-08-25 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CA2217545A1 (en) | 1995-04-11 | 1996-10-17 | Marc Vidal | Reverse two-hybrid systems |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| CA2297489A1 (en) | 1997-07-30 | 1999-02-11 | Emory University | Novel bone mineralization proteins, dna, vectors, expression systems |
| BR0008188A (pt) | 1999-01-21 | 2002-02-13 | Metamorphix Inc | Inibidores de fator de diferenciação de crescimento e usos para os mesmos |
| EP1729793B1 (en) | 2004-03-02 | 2015-07-22 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors for muscle wasting disorders |
| ES2551852T3 (es) | 2004-07-23 | 2015-11-24 | Acceleron Pharma Inc. | Polipéptidos del receptor ActRII |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| EP2468291B1 (en) | 2006-12-18 | 2017-11-22 | Acceleron Pharma, Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| TWI782836B (zh) * | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| TWI586364B (zh) | 2008-05-02 | 2017-06-11 | 艾西利羅製藥公司 | 調節血管新生與周圍細胞組成的方法與組合物 |
| NZ590326A (en) | 2008-06-26 | 2013-05-31 | Acceleron Pharma Inc | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| JP5922928B2 (ja) | 2008-08-14 | 2016-05-24 | アクセルロン ファーマ， インコーポレイテッド | 赤血球レベルを高めるためのｇｄｆトラップの使用 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| EP2387412A4 (en) | 2009-01-13 | 2013-04-03 | Acceleron Pharma Inc | PROCESS FOR INCREASING THE ADIPONECTIN MIRROR |
| CN102548617B (zh) | 2009-03-30 | 2017-11-07 | 阿塞勒隆制药公司 | Bmp‑alk3拮抗剂和促进骨生长的用途 |
| EP2440577A4 (en) * | 2009-06-12 | 2013-01-23 | Acceleron Pharma Inc | SHORTEN ACTRIIB FC FUSION PROTEINS |
| ES2796121T3 (es) | 2009-08-13 | 2020-11-25 | Acceleron Pharma Inc | Uso combinado de trampas de GDF y activadores del receptor de la eritropoyetina para aumentar los niveles de glóbulos rojos |
| CA2773494A1 (en) * | 2009-09-09 | 2011-03-17 | Acceleron Pharma Inc. | Actriib antagonists and dosing and uses thereof |
| CA2781519A1 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| WO2012027065A2 (en) | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| CN102850458B (zh) | 2011-06-28 | 2014-10-01 | 华博生物医药技术（上海）有限公司 | 新型重组双功能融合蛋白及其制法和用途 |
| CA2852683A1 (en) | 2011-10-17 | 2013-04-25 | Acceleron Pharma, Inc. | Methods and compositions for treating ineffective erythropoiesis |
| WO2013063536A1 (en) | 2011-10-27 | 2013-05-02 | Acceleron Pharma, Inc. | Actriib binding agents and uses thereof |
| CN105658672A (zh) | 2013-08-22 | 2016-06-08 | 阿塞勒隆制药公司 | TGF-β受体II型变体及其用途 |
| KR102520970B1 (ko) * | 2014-03-21 | 2023-04-12 | 악셀레론 파마 인코포레이티드 | 액티빈 b 및/또는 gdf11을 억제함으로써 적혈 혈액 세포 수준을 증가시키고 비효율적인 적혈구 생성을 치료하는 방법 |
| JP6649895B2 (ja) * | 2014-04-18 | 2020-02-19 | アクセルロン ファーマ， インコーポレイテッド | 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法 |
| AU2015274277B2 (en) * | 2014-06-13 | 2021-03-18 | Acceleron Pharma, Inc. | Methods and compositions for treating ulcers |
| SMT202300166T1 (it) | 2014-12-03 | 2023-07-20 | Celgene Corp | Antagonisti di attivina- actrii e usi per il trattamento di sindrome mielodisplastica |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| BR112017021510A2 (pt) | 2015-04-06 | 2018-07-03 | Acceleron Pharma Inc | heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização |
| JP6810702B2 (ja) | 2015-04-06 | 2021-01-06 | アクセルロン ファーマ インコーポレイテッド | シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用 |
| RS61881B1 (sr) | 2015-04-22 | 2021-06-30 | Biogen Ma Inc | Novi hibridni actriib proteini zamke za ligand za lečenje bolesti gubljenja mišića |
| WO2016205370A1 (en) | 2015-06-15 | 2016-12-22 | Santa Maria Biotherapeutics, Inc. | Methods of using activin receptor iib-based proteins |
| EP3344660B1 (en) | 2015-08-31 | 2025-03-05 | National Research Council of Canada | Tgf-beta-receptor ectodomain fusion molecules and uses thereof |
| EP3439741A4 (en) | 2016-04-06 | 2020-05-06 | Acceleron Pharma Inc. | ALK7 ANTAGONISTS AND USES THEREOF |
| AU2017293778B2 (en) | 2016-07-07 | 2022-03-24 | Acceleron Pharma Inc. | TGF-beta superfamily heteromultimers and uses thereof |
| WO2018067874A1 (en) | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Variant actriib proteins and uses thereof |
| EP3522913A4 (en) | 2016-10-05 | 2020-10-28 | Acceleron Pharma Inc. | ALK4 HETEROMULTIMERS: ACTRIIB AND THEIR USES |
| AU2017338915B2 (en) | 2016-10-05 | 2024-11-21 | Acceleron Pharma Inc. | TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| EP3538123A4 (en) | 2016-11-10 | 2020-10-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE IIA VARIANTS AND THEIR METHODS OF USE |
-
2017
- 2017-10-05 WO PCT/US2017/055421 patent/WO2018067874A1/en not_active Ceased
- 2017-10-05 EP EP17859219.2A patent/EP3523328A4/en active Pending
- 2017-10-05 BR BR112019006918A patent/BR112019006918A2/pt unknown
- 2017-10-05 JP JP2019518302A patent/JP7280182B2/ja active Active
- 2017-10-05 KR KR1020197012902A patent/KR102595559B1/ko active Active
- 2017-10-05 KR KR1020237036672A patent/KR102761094B1/ko active Active
- 2017-10-05 US US16/340,048 patent/US11267865B2/en active Active
- 2017-10-05 AU AU2017338916A patent/AU2017338916B2/en active Active
- 2017-10-05 MA MA046471A patent/MA46471A/fr unknown
- 2017-10-05 CN CN201780074935.6A patent/CN110036025B/zh active Active
- 2017-10-05 CA CA3039525A patent/CA3039525A1/en active Pending
-
2022
- 2022-03-07 US US17/687,934 patent/US12240887B2/en active Active
- 2022-03-11 AU AU2022201698A patent/AU2022201698A1/en not_active Abandoned
-
2023
- 2023-01-19 JP JP2023006458A patent/JP7617962B2/ja active Active
-
2024
- 2024-02-05 AU AU2024200684A patent/AU2024200684A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019536440A5 (enExample) | ||
| Steverding | The transferrin receptor of Trypanosoma brucei | |
| JP2020530293A5 (enExample) | ||
| CN107847561B (zh) | TGF-β超家族I型和II型受体异多聚体及其用途 | |
| CN103732628B (zh) | 多价杂多聚体骨架设计和构建体 | |
| US11352413B2 (en) | Engineered PD-1 variants | |
| JP2018516092A5 (enExample) | ||
| JP2019506166A5 (enExample) | ||
| JP2018525006A5 (enExample) | ||
| JP2019516663A5 (enExample) | ||
| JP2016052315A5 (enExample) | ||
| JP2021512624A (ja) | 抗ｐｄ−１／抗ｖｅｇｆ天然抗体構造様ヘテロ二量体型二重特異性抗体及びその製造 | |
| JP2019535268A5 (ja) | アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物 | |
| JP2020505034A5 (enExample) | ||
| JP2019506841A5 (enExample) | ||
| JP2020505475A5 (enExample) | ||
| RU2010122053A (ru) | Иммуносупрессорные полипептиды и нуклеиновые кислоты | |
| AU2013289881A1 (en) | Multivalent heteromultimer scaffold design and constructs | |
| JP2014508510A5 (enExample) | ||
| JPWO2020181094A5 (enExample) | ||
| JP2013505713A5 (enExample) | ||
| TW202130363A (zh) | 變異型ｒｓｖ ｆ蛋白質及其利用 | |
| CN107207622B (zh) | Hla-b27同二聚体用于癌症治疗的用途 | |
| JP2019520038A5 (enExample) | ||
| FI4034555T3 (fi) | Dap10/dap12-fuusiopolypeptidit |